Indeed, bortezomib has been found to lead to increased β-catenin accumulation in tumor cells, and β-catenin has separately been shown to drive the expression of ALDH in radio-resistant prostate cancer cells [41,42]. The gene discussed is LDHA; the disease is prostate cancer.